Clinical Trial Results: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and pharmacokinetics of intravenous fixed-dose tiragolumab plus atezolizumab in PD-L1–selected solid tumors completed with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pd-l1 Selected Solid Tumors

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: PD-L1-selected Solid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2026-06-18